Scarica l'app Stockscreener
3.11
6.87%
0.20
Dopo l'orario di chiusura:
3.10
-0.010
-0.32%
Precedente Chiudi:
$2.91
Aprire:
$2.95
Volume 24 ore:
50,493
Relative Volume:
0.83
Capitalizzazione di mercato:
$36.13M
Reddito:
-
Utile/perdita netta:
$-6.01M
Rapporto P/E:
-2.5241
EPS:
-1.2321
Flusso di cassa netto:
$-5.71M
1 W Prestazione:
+9.12%
1M Prestazione:
+0.00%
6M Prestazione:
-26.48%
1 anno Prestazione:
+150.81%
Intervallo 1D:
$2.95
$3.16
Intervallo di 1 settimana:
$2.71
$3.16
Portata 52W:
$0.64
$6.26
Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile
Nome
Lixte Biotechnology Holdings Inc
Settore
Industria
Telefono
310 203 2902
Indirizzo
433 PLAZA REAL, BOCA RATON
Compare LIXT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LIXT
Lixte Biotechnology Holdings Inc
|
3.11 | 33.81M | 0 | -6.01M | -5.71M | -1.2321 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lixte Biotechnology Holdings Inc Borsa (LIXT) Ultime notizie
Lixte Biotechnology Holdings, Inc. (LIXTW) - Minichart
LIXTE Biotechnology Reports Promising Interim Ovarian Cancer Trial Results at SGO Conference - citybuzz -
LIXTE Biotechnology (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference - USA Today
LIXTE Biotechnology (LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference - NewMediaWire
Options Flow: What is the next catalyst for Lixte Biotechnology Holdings Inc Equity Warrant2026 Macro Impact & AI Forecast Swing Trade Picks - baoquankhu1.vn
Promising Clinical Trial Results for Lixte Biotechnology (LIXT) - GuruFocus
Ovarian cancer trial expands after 40% disease control in 20 patients - Stock Titan
Geopolitics Watch: How volatile is Lixte Biotechnology Holdings Inc stock2026 Catalysts & Risk Controlled Daily Trade Plans - baoquankhu1.vn
LIXTE Biotechnology Expands Cancer Treatment Strategy with Acquisition and Clinical Advancements - citybuzz -
Lixte Biotech Holdings (LIXT) Advances Precision Oncology Strategy With LB-100, Expands Clinical and Strategic Partnerships - NewMediaWire
Lixte Biotech Holdings (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships - Financial-News.co.uk
Aug Reactions: What is the cash position of Lixte Biotechnology Holdings Inc2026 Fundamental Recap & Intraday High Probability Setup Alerts - baoquankhu1.vn
Retail Trends: What are the future prospects of Mineralys Therapeutics Inc2026 Sentiment & Community Shared Stock Ideas - baoquankhu1.vn
Lixte Biotech Advances Precision Oncology Strategy with LB-100 Therapy and Expanded Partnerships - citybuzz -
Valuation Update: Is Airship AI Holdings Inc part of any ETFPortfolio Risk Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Risk Off: Is Lixte Biotechnology Holdings Inc attractive for institutional investors2026 Price Targets & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
ETF Watch: Is Lixte Biotechnology Holdings Inc affected by consumer sentiment2026 Technical Overview & Daily Volume Surge Trade Alerts - baoquankhu1.vn
LIXT Technical Analysis & Stock Price Forecast - Intellectia AI
Investor Mood: Is Lixte Biotechnology Holdings Inc stock forming a triangle pattern2026 Snapshot & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
LIXT PE Ratio & Valuation, Is LIXT Overvalued - Intellectia AI
Lixte Biotechnology Holdings, Inc. (LIXTW) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
LIXTE Biotechnology Holdings (LIXT) Files 2025 Form 10-K, Highlights Transformational Year - newmediawire.com
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year - Financial-News.co.uk
LIXTE Biotechnology’s LB-100 May Transform Cancer Treatment—Yet Time Remains the Deciding Factor - bitget.com
LIXTE Biotechnology (LIXT) Has the World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes - NewMediaWire
LIXTE Biotechnology (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes - TipRanks
LIXTE Biotechnology Reports Transformational Year with Clinical Progress and Strategic Expansion - citybuzz -
LIXTE Biotechnology (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials - TipRanks
Lixte Biotech Receives Going Concern Alert Amid Insider and Institutional Sell-Offs—Who Will Fund the Recovery? - Bitget
LIXTE Biotechnology (LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials - NewMediaWire
LIXTE Biotechnology's LB-100 Emerges as Sole Clinical-Stage PP2A Inhibitor in Cancer Treatment Development - citybuzz -
LIXTE Biotechnology Reports Progress on LB-100 in 2025 Annual Report with Expanded Clinical Trials and Collaborations - geneonline.com
Cancer drug study doubles to 42 patients after LIXTE's $11M raise - Stock Titan
LIXTE Biotechnology’s Expanded Trial Could Be Its Best Shot at Breaking the Stagnation - Bitget
Lixte Biotechnology | 10-K: FY2025 Annual Report - Moomoo
Lixte Biotechnology Holdings 10-K: $0 Revenue, $(1.26) EPS - TradingView — Track All Markets
Lixte Biotechnology (NASDAQ: LIXT) posts larger loss and flags going-concern risk - Stock Titan
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
LIXTE Biotechnology Expands Clinical Trials for LB-100 in Challenging Ovarian and Colon Cancers - citybuzz -
Quarterly Earnings: Is Lixte Biotechnology Holdings Inc attractive for institutional investorsWeekly Trade Report & Daily Profit Focused Screening - baoquankhu1.vn
Lixte Biotechnology Holdings, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Lixte Biotechnology Stock: Precision Oncology Pioneer with High-Risk Development Pipeline for North - AD HOC NEWS
Lixte Biotech (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership - Benzinga
De La Soul Set to Lead Good Health Summit at Morehouse College - EBONY Magazine
Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (NASDAQ: LIXT) Saw It Coming - The Globe and Mail
Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (LIXT) Saw It Coming - NewMediaWire
Treasury Yields: Can Lixte Biotechnology Holdings Inc Equity Warrant sustain its profitabilityEarnings Growth Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Pharma News: Whats the profit margin of Lixte Biotechnology Holdings IncStock Surge & Safe Capital Growth Trade Ideas - baoquankhu1.vn
LIXTE Biotechnology (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape - The Globe and Mail
LIXTE Biotechnology (LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape - NewMediaWire
Lixte Biotechnology Holdings Inc Azioni (LIXT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):